R
Randall F. Holcombe
Researcher at University of Hawaii
Publications - 53
Citations - 2035
Randall F. Holcombe is an academic researcher from University of Hawaii. The author has contributed to research in topics: Cancer & Wnt signaling pathway. The author has an hindex of 19, co-authored 53 publications receiving 1607 citations. Previous affiliations of Randall F. Holcombe include Mount Sinai Hospital & Icahn School of Medicine at Mount Sinai.
Papers
More filters
Journal ArticleDOI
Sustained proliferation in cancer: Mechanisms and novel therapeutic targets
Mark A. Feitelson,Alla Arzumanyan,Rob J. Kulathinal,Stacy W. Blain,Randall F. Holcombe,Jamal Mahajna,Maria Marino,María L. Martínez-Chantar,Roman Nawroth,Isidro Sánchez-García,Dipali Sharma,Neeraj K. Saxena,Neetu Singh,Panagiotis J. Vlachostergios,Shanchun Guo,Kanya Honoki,Hiromasa Fujii,Alexandros G. Georgakilas,Alan Bilsland,Amedeo Amedei,Elena Niccolai,Amr Amin,S. Salman Ashraf,Chandra S. Boosani,Gunjan Guha,Maria Rosa Ciriolo,Katia Aquilano,Sophie Chen,Sulma I. Mohammed,Asfar S. Azmi,Dipita Bhakta,Dorota Halicka,W. Nicol Keith,Somaira Nowsheen +33 more
TL;DR: Natural compounds found to inhibit one or more pathways that contribute to proliferation have been found and will be very important for identifying signaling pathways and molecular targets that may provide early diagnostic markers and/or critical targets for the development of new drugs or drug combinations that block tumor formation and progression.
Journal ArticleDOI
Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer.
Sunil R. Hingorani,Sunil R. Hingorani,William P. Harris,J. Thaddeus Beck,Boris A. Berdov,Stephanie Ann Wagner,Eduard M. Pshevlotsky,Sergei Tjulandin,Oleg Gladkov,Randall F. Holcombe,Ronald L. Korn,Natarajan Raghunand,Samuel S. Dychter,Ping Jiang,H. Michael Shepard,Craig Devoe +15 more
TL;DR: PEGPH20 in combination with Gem was well tolerated and may have therapeutic benefit in patients with advanced PDA, especially in those with high HA tumors.
Journal ArticleDOI
Designing a broad-spectrum integrative approach for cancer prevention and treatment
Keith I. Block,Charlotte Gyllenhaal,Leroy Lowe,Amedeo Amedei,A.R.M. Ruhul Amin,Amr Amin,Katia Aquilano,Jack L. Arbiser,Jack L. Arbiser,Alexandra Arreola,Alla Arzumanyan,S. Salman Ashraf,Asfar S. Azmi,Fabian Benencia,Dipita Bhakta,Alan Bilsland,Anupam Bishayee,Stacy W. Blain,Penny B. Block,Chandra S. Boosani,Thomas E. Carey,Amancio Carnero,Marianeve Carotenuto,Stephanie C. Casey,Mrinmay Chakrabarti,Rupesh Chaturvedi,Georgia Zhuo Chen,Helen Chen,Sophie Chen,Yi Charlie Chen,Beom K. Choi,Maria Rosa Ciriolo,Helen M. Coley,Andrew Collins,Marisa Connell,Sarah Crawford,Colleen S. Curran,Charlotta Dabrosin,Giovanna Damia,Santanu Dasgupta,Ralph J. DeBerardinis,William K. Decker,Punita Dhawan,Anna Mae Diehl,Jin-Tang Dong,Q. Ping Dou,Janice E. Drewa,Eyad Elkord,Bassel F. El-Rayes,Mark A. Feitelson,Dean W. Felsheru,Lynnette R. Ferguson,Carmela Fimognari,Gary L. Firestone,Christian Frezza,Hiromasa Fujii,Mark M. Fuster,Daniele Generali,Alexandros G. Georgakilas,Frank Gieseler,Michael Gilbertson,Michelle F. Green,Brendan Grue,Gunjan Guhal,Dorota Halicka,William G. Helferich,Petr Heneberg,Patricia Hentosh,Matthew D. Hirschey,Lorne J. Hofseth,Randall F. Holcombe,Kanya Honoki,Hsue-Yin Hsu,Gloria S. Huang,Lasse Jensen,Lasse Jensen,Wen Guo Jiang,Lee W. Jones,Phillip Karpowicz,W. Nicol Keith,Sid P. Kerkar,Gazala Khan,Mahin Khatami,Young Hee Ko,Omer Kucuk,Rob J. Kulathinal,Nagi B. Kumar,Byoung S. Kwon,Anne Leb,Michael A. Leab,Ho Young Lee,Terry Lichtor,Liang Tzung Lin,Jason W. Locasale,Balakrishna L. Lokeshwar,Valter D. Longo,Costas A. Lyssiotis,Karen L. MacKenzie,Meenakshi Malhotra,Maria Marino,María L. Martínez-Chantar,Ander Matheu,Christopher Maxwellx,Eoin McDonnell,Alan K. Meeker,Mahya Mehrmohamadi,Kapil Mehta,Gregory A. Michelotti,Ramzi M. Mohammad,Sulma I. Mohammed,D. James Morré,Irfana Muqbil,Vinayak Muralidharcq,Vinayak Muralidharcq,Michael P. Murphy,Ganji Purnachandra Nagaraju,Rita Nahta,Elena Niccolai,Somaira Nowsheen,Carolina Panis,Francesco Pantano,Virginia R. Parslow,Graham Pawelec,Peter L. Pedersen,Brad Poore,Deepak Poudyal,Satya Prakash,Mark E. Prince,Lizzia Raffaghello,Jeffrey C. Rathmell,W. Kimryn Rathmell,Swapan K. Ray,Jörg Reichrath,Sarallah Rezazadeh,Domenico Ribatti,Luigi Ricciardiello,R. Brooks Robeydf,R. Brooks Robeydf,Francis Rodierdh,H.P. Vasantha Rupasinghe,Gian Luigi Russo,Elizabeth P. Ryan,Abbas Samadi,Isidro Sánchez-García,Andrew James Sanders,Daniele Santini,Malancha Sarkar,Tetsuro Sasada,Neeraj K. Saxena,Rodney E. Shackelford,H. M. C. Shantha Kumara,Dipali Sharma,Dong M. Shin,David Sidransky,Markus D. Siegelin,Emanuela Signori,Neetu Singh,Sharanya Sivanand,Daniel Sliva,Carl Smythe,Carmela Spagnuolo,Diana M. Stafforini,John Stagg,Pochi R. Subbarayan,Tabetha Sundin,Wamidh H. Talib,Sarah K. Thompson,Phuoc T. Tran,Hendrik Ungefroren,Matthew G. Vander Heiden,Vasundara Venkateswaran,Dass S. Vinay,Panagiotis J. Vlachostergios,Zongwei Wang,Kathryn E. Wellen,Richard L. Whelan,Eddy S. Yang,Huanjie Yang,Xujuan Yang,Paul Yaswen,Clement G. Yedjou,Xin Yin,Jiyue Zhu,Massimo Zollo +183 more
TL;DR: An international task force of 180 scientists was assembled to explore the concept of a low-toxicity "broad-spectrum" therapeutic approach that could simultaneously target many key pathways and mechanisms, and results suggest that a broad-spectrums approach should be feasible from a safety standpoint.
Journal ArticleDOI
Wnt signaling and colon carcinogenesis: beyond APC.
TL;DR: Regulatory pathways that influence Wnt signaling highlight how it might be possible to design therapies that target a network of signals beyond that of APC and β-catenin.
Journal ArticleDOI
Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets
Benjamin A. Weinberg,Joanne Xiu,Michael R. Lindberg,Anthony F. Shields,Jimmy J. Hwang,Kelsey Poorman,Mohamed E. Salem,Michael J. Pishvaian,Randall F. Holcombe,John L. Marshall,Michael A. Morse +10 more
TL;DR: Findings support clinical molecular profiling of BTCs to inform potential therapeutic selection and clinical trial design based on the primary tumor's site of origin within the biliary tree.